Xu Yue, Wang Ying-Ming, Sun Zheng-Tai, Yang Xiao-Long, Zhuang Xin-Yu, Ren Ya-Ru, Chen Ying-Jie, Chen Feng, Ma Xiao, Tang Xiao-Wen, Zhang Xiao-Feng
Department of Ophthalmology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China.
Department of Ophthalmology, First Affiliated Hospital of Soochow University, Suzhou, China.
Front Oncol. 2022 Sep 15;12:962250. doi: 10.3389/fonc.2022.962250. eCollection 2022.
Corneal perforation is a rare and serious complication of ocular graft-versus-host disease (oGVHD) patients. This study was to retrospectively report seven corneal perforation patients after allogeneic hematopoietic stem cell transplantation (HSCT). Demographic, hematologic, and ophthalmological data of patients were clarified in detail. Nine eyes of seven corneal perforation patients were clarified (Cases 3 and 6 were bilateral and the others are unilateral). All the cases had other affected GVHD organs, especially skin involvement. The duration between HSCT and corneal perforation was usually long with 21 (17-145) months as median interval, whereas the duration between oGVHD diagnosis and corneal perforation was relatively shorter with 4 (2-81) months as median interval. Most patients presented to ophthalmology department with poor visual acuity, BUT and Schirmer's test. Eyelid marginal hyperemia and irregularity were observed in most corneal perforation eyes. Keratoplasty or conjunctival flap covering (CFC) surgeries was performed after corneal perforation. After a long-term follow-up for most patients (median 21 months, range: 2-86 months), only two eyes of two patients (22.22%) had a final BCVA of 20/100 or better. Patients involved in both cutaneous GVHD and blepharitis indicate the aggressive development of oGVHD. Early diagnosis, long-term follow-up, and effective multi-disciplinary treatments for oGVHD patients are essential. Corticosteroids and immunosuppressor remain essential, whereas the use of topical corticosteroids should be carefully considered in corneal ulceration patients. In addition, appropriate surgeries should be performed to control oGVHD development in time.
角膜穿孔是眼部移植物抗宿主病(oGVHD)患者罕见且严重的并发症。本研究旨在回顾性报告7例异基因造血干细胞移植(HSCT)后发生角膜穿孔的患者。详细阐明了患者的人口统计学、血液学和眼科数据。明确了7例角膜穿孔患者的9只眼(病例3和6为双眼,其余为单眼)。所有病例均有其他受影响的GVHD器官,尤其是皮肤受累。HSCT与角膜穿孔之间的时间通常较长,中位间隔为21(17 - 145)个月,而oGVHD诊断与角膜穿孔之间的时间相对较短,中位间隔为4(2 - 81)个月。大多数患者因视力差、泪膜破裂时间(BUT)和泪液分泌试验(Schirmer试验)而就诊于眼科。大多数角膜穿孔眼观察到睑缘充血和不规则。角膜穿孔后进行了角膜移植术或结膜瓣覆盖(CFC)手术。对大多数患者进行长期随访(中位21个月,范围:2 - 86个月)后,只有2例患者的2只眼(22.22%)最终最佳矫正视力(BCVA)达到20/100或更好。皮肤GVHD和睑缘炎均受累的患者提示oGVHD进展迅速。对oGVHD患者进行早期诊断、长期随访和有效的多学科治疗至关重要。皮质类固醇和免疫抑制剂仍然必不可少,而在角膜溃疡患者中应谨慎考虑使用局部皮质类固醇。此外,应及时进行适当的手术以控制oGVHD的发展。